ORTHOFIX MEDICAL (OFIX) to Release Quarterly Earnings on Tuesday

Key Points

• Orthofix Medical is set to announce its Q2 2025 earnings results on August 5th, with expectations of earnings at $0.04 per share and revenue of $196.89 million.
• CEO Massimo Calafiore recently purchased 10,000 shares at an average price of $12.54, increasing his stake in the company to approximately $2.94 million.
• Analysts have mixed ratings for Orthofix Medical, with an average rating of "Moderate Buy" and a notable price target of $21.50.

ORTHOFIX MEDICAL (NASDAQ:OFIX - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $196.89 million for the quarter.

ORTHOFIX MEDICAL Trading Down 1.5%

NASDAQ OFIX traded down $0.17 during trading hours on Wednesday, reaching $11.36. The company's stock had a trading volume of 272,904 shares, compared to its average volume of 264,245. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.71 and a quick ratio of 1.50. ORTHOFIX MEDICAL has a 52 week low of $10.24 and a 52 week high of $20.73. The firm has a fifty day simple moving average of $11.04 and a 200-day simple moving average of $14.22. The stock has a market cap of $445.08 million, a P/E ratio of -3.08 and a beta of 0.80.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of ORTHOFIX MEDICAL from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. JMP Securities reaffirmed a "market perform" rating on shares of ORTHOFIX MEDICAL in a report on Friday, June 6th. Finally, Barrington Research raised shares of ORTHOFIX MEDICAL to a "strong-buy" rating and set a $16.00 price target on the stock in a report on Monday, June 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $21.50.

Insider Activity

In other ORTHOFIX MEDICAL news, insider Aviva Mcpherron sold 3,728 shares of the company's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total value of $39,181.28. Following the completion of the sale, the insider owned 46,322 shares of the company's stock, valued at $486,844.22. This represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Engine Capital Management, Lp bought 100,000 shares of the business's stock in a transaction on Wednesday, May 7th. The stock was purchased at an average cost of $12.31 per share, with a total value of $1,231,000.00. Following the purchase, the insider owned 3,544,807 shares of the company's stock, valued at $43,636,574.17. This represents a 2.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 113,500 shares of company stock worth $1,394,858 over the last ninety days. Company insiders own 1.30% of the company's stock.

Institutional Trading of ORTHOFIX MEDICAL

A number of institutional investors have recently made changes to their positions in OFIX. Strs Ohio bought a new position in shares of ORTHOFIX MEDICAL during the first quarter valued at approximately $150,000. AQR Capital Management LLC increased its holdings in ORTHOFIX MEDICAL by 67.7% in the 1st quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company's stock worth $333,000 after buying an additional 8,241 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in ORTHOFIX MEDICAL by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company's stock worth $335,000 after buying an additional 1,213 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in ORTHOFIX MEDICAL in the first quarter worth about $1,076,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

About ORTHOFIX MEDICAL

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.